Further details on identity and specification of active substance are provided in the review report.    ,

‘353,  Paclobutrazol    CAS No: 76738-62-0    CIPAC No: 445  ,(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol,≥ 930 g/kg,1 June 2011,31 May 2021,  PART A   Only uses as plant growth regulator may be authorised.     PART B   For the implementation of the uniform principles of Annex VI, the conclusions of the review report on paclobutrazol, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 11 March 2011 shall be taken into account.    In this overall assessment Member States shall pay particular attention to the risk to aquatic plants and ensure that conditions of use include the risk mitigation measures, where appropriate.    The Member States concerned shall request the submission of confirmatory information as regards:       the specification of the technical material, as commercially manufactured;      the analytical methods in soil and surface water for the metabolite NOA457654;      the residues of triazole derivative metabolites (TDMs) in primary crops, rotational crops and products of animal origin;      the potential endocrine disrupting properties of paclobutrazol;      the potential adverse effects of breakdown products of the different optical structures of paclobutrazol and its metabolite CGA 149907 on the environmental compartments soil, water and air.       The Member States concerned shall ensure that the applicant submits to the Commission the information set out in points (1) and (2) by 30 November 2011, the information set out in points (3) by 31 May 2013, the information set out in point (4) within two years after the adoption of the OECD test guidelines on endocrine disruption and the information set out in point (5) within two years after the adoption of specific guidance.’   ,